Organon & Co. Income (Loss) from Continuing Operations, Per Basic Share
Organon & Co. (OGN) reported Income (Loss) from Continuing Operations, Per Basic Share of $4.01 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2024-02-26
- Organon & Co. income (loss) from continuing operations, per basic share for the quarter ending 2022-09-30 was $0.89, a 29.92% decline year-over-year.
- Organon & Co. income (loss) from continuing operations, per basic share for the quarter ending 2022-06-30 was $0.92, a 45.88% decline year-over-year.
- Organon & Co. income (loss) from continuing operations, per basic share for the quarter ending 2022-03-31 was $1.37, a 12.18% decline year-over-year.
- Organon & Co. income (loss) from continuing operations, per basic share for the quarter ending 2021-09-30 was $1.27, a 42.53% decline year-over-year.
- Organon & Co. income (loss) from continuing operations, per basic share for fiscal 2023 was $4.01, a 11.08% increase from fiscal 2022.
- Organon & Co. income (loss) from continuing operations, per basic share for fiscal 2022 was $3.61, a 32.27% decline from fiscal 2021.
- Organon & Co. income (loss) from continuing operations, per basic share for fiscal 2021 was $5.33, a 40.11% decline from fiscal 2020.
- Organon & Co. income (loss) from continuing operations, per basic share for fiscal 2020 was $8.90, a 31.75% decline from fiscal 2019.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|
| 2023-12-31 | $4.01 10-K · filed 2024-02-26 | |||
| 2022-12-31 | $3.61 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $0.89 10-Q · filed 2022-11-04 | $3.19 10-Q · filed 2022-11-04 | ||
| 2022-06-30 | $0.92 10-Q · filed 2022-08-05 | $2.29 10-Q · filed 2022-08-05 | ||
| 2022-03-31 | $1.37 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | $5.33 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $1.27 10-Q · filed 2022-11-04 | $4.53 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | $1.70 10-Q · filed 2022-08-05 | $3.26 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $1.56 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $8.90 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $2.21 10-Q · filed 2021-11-12 | $7.42 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $2.31 10-Q · filed 2021-08-16 | $5.21 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $2.90 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $13.04 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |